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Introduction
Do we need yet another review on alternative methods in im-
munotoxicology? the authors have contributed to many that 
have already been published (Gennari et al., 2005; Corsini, 
2006; Carfì et al., 2007; Corsini and Roggen, 2009; Galbiati et 
al., 2010; lankveld et al., 2010; Pfaller et al., 2010). Immuno-
toxicology in general is also well covered in reviews and book 
chapters (Descotes, 2004, 2006; Kadow et al., 2009; Dietert, 
2010; House, 2010; Rooney et al., 2012), and is even the sub-
ject of entire textbooks (Dean et al., 1994; House et al., 2006), 
though arguably the latter may no longer be entirely up to date. 
that is why this review is not another attempt to sum up the 
state of the art but to ask some fundamental but out of the box 
questions. 
Cambridge Advanced learner’s Dictionary & thesaurus de-
fines “immunology” as “the study of how the body fights disease 
and infection”1. toxic immunomodulation would then mean 
either excess or deficiency in fighting disease and infection. Ex-
cess situations could be seen, for example, in cases of allergy 
and sensitization, where essentially harmless antigens trigger 
excessive defense. these are extensively covered in the above-
mentioned reviews; here, only autoimmunity and pyrogenicity/
inflammation will be touched on as examples of inappropriate 
immunoactivation. Defective situations could be seen for ex-
ample in cases of primary and secondary immunodeficiency, 
which result in increased susceptibility to pathogenic infection 
and cancer (Gallagher et al., 2010; Riminton et al., 2011). this 
review will primarily focus on toxic immunosuppression. 
the only remark concerning hypersensitivity we want to 
make is that allergic contact dermatitis is to a considerable ex-
tent a preventable disease. there is a pressing need for alter-
native, non-animal methods to reduce and ultimately replace 
animal tests for this endpoint, as also required by some eu-
ropean regulations (i.e., Cosmetics Regulation and ReACH). 
the correct detection of skin sensitizers, the characterization 
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compounds entering the human system through environmen-
tal and/or occupational exposure can be very difficult (Colo-
sio et al., 2005).
On the other hand, we can look at the immune system as a 
whole and measure the impact of chemicals on its overall func-
tion, i.e., does chemical exposure lead to infection and cancer? 
Clinical grade immunosuppression indeed results in increased 
cancer manifestations: 5 years of cyclosporine A treatment in-
creases the risk for any kind of cancer 3-4 fold (Sodeman et 
al., 2011). Any significant change induced by xenobiotic expo-
sure on the functionality of immune cells must be considered a 
hazard, whose effective risk for human beings should be care-
fully evaluated during the risk assessment phase. If a chemical 
is immunotoxic and, in particular, if it affects NK cell activity 
and cell-mediated immune responses, this may represent a risk 
for decreased immune surveillance and cancer. Immunotoxic-
ity assays might therefore play a role in future integrated test-
ing strategies for carcinogenicity, representing a non-genotoxic 
mechanism of carcinogenicity (Basketter et al., 2012).
Immunocompetence is only one parameter beside the physi-
ological and genetic factors, and exposure to infectious agents 
at different doses and degrees of virulence. It changes the odds 
in the lottery of infection. this is likely the reason why im-
munotoxicity does not follow a threshold model – missing a 
single virus or bacterium can result in an infection. the prob-
ability is low for the individual, but on the level of populations 
we might see an effect (Germolec, 2004). Still, it is difficult 
to assess whether mild to moderate immunotoxicity caused by 
chemical exposure predisposes to infections of the upper respi-
ratory tract or re-activation of latent viruses (herpes), the most 
common manifestations of therapeutic immunosuppression. As 
cited below, there is not much such evidence in humans: Immu-
nosuppression induced by pesticides may explain the increased 
incidence of infections in humans observed in several studies 
(reviewed in Corsini et al., 2013) and two recently published 
studies indicate that perfluorinated compounds, an important 
class of environmental contaminants commonly detected in 
blood samples from both wildlife and humans, may lower vac-
cine protection in children (Grandjean et al., 2012; Granum et 
al., 2013). Further studies are clearly needed to address this 
critical point.
Consideration 1: 
What is immunotoxicity beside clinical 
immunosuppression and inappropriate 
immunostimulation?
the immune system can be seen as a more or less concerted 
system of armies carrying different varieties of weapons to act 
against different enemies. It defends the body but can also turn 
against it. It is among the fastest dividing organs together with 
gut mucosa (under permanent digestion) and hair follicles, as 
evidenced by the typical and dose limiting side effects of chemo- 
therapy, the most extreme (therapeutic) intoxication of humans 
performed on a regular basis, with a lethality of up to 10%. 
of potency, the understanding of human skin exposure, and the 
application of adequate risk assessment and management strat-
egies can all contribute to a reduction of allergic contact der-
matitis. A range of in vivo methods exist that have been proven 
to be very accurate in terms of the predictive identification of 
sensitizers. the challenge is to obtain the same quality of in-
formation using in silico or in vitro methods (Basketter et al., 
2012). even if no validated tests are yet available, important 
progress in the last decades has resulted in the development 
of alternative methods that could lead to the replacement of 
the existing animal models in the near future. At present, three 
non-animal test methods, namely the Direct Peptide Reactivity 
Assay (DPRA), the Keratinosens™ and the human Cell line 
Activation test (hClAt) are under formal validation at eURl 
eCVAM for their potential to predict skin sensitization poten-
tial, while the Myeloid U937 Skin Sensitisation test (MUSSt) 
has been discontinued due to transferability problems. Results 
are expected at the end of 2013. It has been predicted, how-
ever, that it will take at least another 7-9 years for the full re-
placement of the in vivo animal models for sensitization (Adler 
et al., 2011). It is expected that in vitro data will be integrated 
into a testing strategy along with peptide reactivity data, bio-
availability data, and some informed rating of structural alerts 
in order to establish an acceptable exposure level (Jaworska et 
al., 2011; Hartung et al., 2013, a t4 workshop report on ItS is 
in preparation).
Immunotoxicology can be defined as the study of adverse ef-
fects on the immune system resulting from occupational, inad-
vertent, or therapeutic exposure to drugs, environmental chemi-
cals and, in some instances, biological materials (House et al., 
2006).
What does the immune system comprise in vertebrates?
1. Innate immunity: a) physical barriers, b) chemical barriers 
(i.e., pH, lipids, enzymes), c) cells (i.e., granulocytes, mono-
cytes/macrophages, natural killer cells);
2. Adaptive immunity: a) humoral (B cells, antibodies), b) cell 
mediated (t cells, lymphokines).
We can look, on the one hand, at possible toxic effects on these 
components. Beside the direct and indirect effects on immune 
cells, we need to consider effects of chemicals on the barriers. 
We should be aware that one of the most critical, i.e., the barrier 
of the gastrointestinal tract, is very little studied. It is constantly 
exposed to foreign antigens present in food and the human gut 
contains about 1-2 kg of bacteria whose possible translocation to 
the systemic circulation is a permanent immunological threat.
No immunotoxicity tests have been conducted on 86% of 
high production volume (HPV) chemicals (eDF, 1997). Al-
though in vitro or ex vivo immune function tests are avail-
able for many components of the immune system, animal 
studies or, occasionally, occupational and clinical studies ex 
vivo or post mortem are used more commonly. However, it is 
not clear whether a certain immunomodulation observed in a 
study model will result in a clinical manifestation, especially 
in a low dose, prolonged exposure scenario. this is a very 
critical issue, because an extrapolation from the high doses 
used in the laboratory model to the low doses of mixtures of 
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this alternative hypothesis. However, this might again be a 
high-dose phenomenon, as it corresponds with clinical experi-
ences, where work exposure and prolonged contact with the 
skin are typically required to result in manifestations. Still, the 
majority of humans do not develop allergies, while our test 
animals react sufficiently uniformly to allow a testing regimen 
with relatively small groups. In susceptible human individu-
als, drugs and chemicals may initiate, facilitate, or exacerbate 
pathological immune processes, resulting in autoimmunity and 
allergy. In principle, they can induce mutations or influence 
the regulation of genes coding for immunoregulatory factors, 
they can modify immune tolerance and regulation, leading to 
immunostimulation as well as immunosuppression. Advances 
over the last decade now bring integrated testing strategies us-
ing in vitro and in silico approaches to replace the animal tests 
into reach (Basketter et al., 2012). Drug allergy is still a sig-
nificant problem and among the most common causes of new 
drugs being withdrawn from the market. 
Autoimmunity is the other most relevant activating derail-
ment of the immune system. this group of diseases is extreme-
ly varied including, among others, autoimmune thyroiditis, 
thrombocytopenia, hemolytic anemia, hepatitis, systemic lu-
pus erythematosus (Sle), insulin-dependent diabetes mellitus, 
myasthenia gravis, multiple sclerosis, and Sjögren’s syndrome. 
there are examples of drugs associated with autoimmune 
phenomena: autoimmune hepatitis (dihydralazine, halothane, 
tienilic acid), drug-induced lupus (dihydralazine, procainamide, 
propylthiouracil), glomerulonephritis (gold thiomalate), and oc-
culomucocutaneous syndrome (practolol). this side effect can 
be quite frequent, e.g., 10-20% of patients receiving procaina-
mide and 5-20% receiving hydralazine develop systemic lupus 
erythematosus (Dean et al., 2007). there is some evidence for 
food and environmental chemicals causing autoimmunity, e.g., 
autoimmune thyroiditis (iodine), scleroderma (l-5-hydrox-
ytryptophan), and Sle (alfalfa seeds). Vinyl chloride, trichlo-
roethylene, aniline (Spanish toxic oil syndrome), tryptophane, 
silica, paraffin, and silicones are among chemicals leading to 
autoimmune manifestations, especially sclerotic and lupus-like 
diseases (Kilburn and Warshaw, 1994). Kosuda and Bigazzi 
(1996) list more than a hundred xenobiotics associated with au-
toimmune disease. Pesticides also have been suggested to play 
a role (Holsapple, 2002). 
A number of syndromes similar to those in humans can be 
mimicked in animals (Pieters, 2007; lam-tse et al., 2002), but 
the diversity of autoimmune diseases limits their utility as a 
screening tool (Luster and Gerberick, 2010). The difficulties 
to study xenobiotic-induced autoimmunity in animal models 
recently have been reviewed (Germolec et al., 2012). these 
models have been used to ascertain a role for mercury and pris-
tine (tMPD) as inducers of autoimmunity and there is some 
evidence for silica, gold, trichloroethylene (tCe), and dioxin 
(tCDD). It appears that chemical-induced autoimmunity is 
rarely organ-specific but more likely systemic. While basic re-
search into autoimmunity also uses in vitro models, e.g., for 
Chemotherapy primarily hits fast dividing cells and thus results 
in hair loss, nausea, and immunosuppression. But we also know 
that it takes strong doses, strict adherence to the dose regimen, 
and often combinations of substances to achieve therapeutic im-
munosuppression, as the immune system recuperates quickly if 
there is a window of reduced immunosuppression as evidenced 
in cases of transplant rejection. 
What we typically see is that there is a fine balance between 
achieving therapeutic immunosuppression to prevent transplant 
rejection and increased incidence of infectious complications. 
this is not surprising, as defense against infections is a key 
function of the immune system. So we can ask, is there any evi-
dence of immunosuppression caused by environmental chemi-
cals that manifests in increased infections?
Infection is the Achilles’ heel of the human body and has only 
been outrun by other diseases as the main cause of death with 
the help of modern medicine. therefore, the immune system 
is under tremendous evolutionary pressure, which has also led 
to tremendous interindividual and interspecies differences. the 
immune system also has enormous overcapacities, as it must be 
the last to fail. this characteristic will predictably buffer chemi-
cal impacts on this organ system and indeed a functional deficit 
often only manifests under the additional stress of mass infec-
tion of an animal. 
the focus on immunosuppression in the study of immuno-
toxicity has been questioned by experts in the field: “Present 
methods of evaluating immunotoxicity are primarily focused 
on immunosuppression, even though unexpected immuno-
suppression has rarely been a cause for concern” (Descotes, 
2006). In industrialized countries hypersensitivity reactions 
represent the most frequently reported immunotoxic effects 
of chemicals. Immunostimulation or “immunoenhancement”, 
i.e., an exaggerated immune response, is known primarily in 
sensitization (allergies, including contact dermatitis) and au-
toimmunity. the clearest disturbance of the immune system, 
indeed, is the dramatically increasing incidence of allergies. 
According to CDC, for example, the prevalence of food aller-
gies in children aged 0-17 years in the US increased between 
1997 and 2011 from 3.4% to 5.1%, and during the same pe-
riod skin allergies increased from 7.4% to 12.5%. there was 
no significant trend in respiratory allergies (around 17.0%)2. 
Some allergies are responses to chemicals and thus it seems 
logical to blame chemical exposure. But is this correct? Pollen 
allergy (hay fever) and food allergy are similarly increasing. 
Many people feel threatened by the ever-increasing number 
of chemicals they are exposed to, but is there a causal link to 
sensitization? First, it appears that the incidence of allergies 
has been increasing continuously over the last century, not re-
ally supporting the hypothesis that a few specific chemicals 
have changed our likeliness to develop sensitization. Could 
instead the exposure to many chemicals with sensitizing or 
immunomodulating potential be causing this? the fact that 
about 35% of all chemicals tested in mice or guinea pigs pro-
duce skin sensitization (Casati et al., 2005) seems to support 
2 http://www.cdc.gov/nchs/data/databriefs/db121.htm
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change to their capacities and reactivity will only become vis-
ible with the appropriate challenge. An impairment of the navy 
will only be visible when the enemy attacks by ship… third, 
and even more complicated, the “balance of powers” typically 
comes with advantages and disadvantages when moving the 
equilibrium. the tH1/tH2 hypothesis, for example, suggests 
that we either defend well against bacteria or against worms. 
Impairing one branch of the immune system would strengthen 
the other. Fourth and last, genetic determinants appear to play 
a major role in immune responses as evidenced, e.g., by the 
greatly different level of sensitivity of different inbred mouse 
strains towards certain pathogens. this will dramatically impair 
our ability to identify health threats in any animal model relying 
on such reduced biological background. Any strategy to cover 
genetic diversity, however, will boost animal or human study 
subject numbers.
the most important aspect is the continuum of immunotox-
icity (Kaminski et al., 2007): it is based on the recognition that 
immune responses in the normal human population vary con-
siderably. this means that immunomodulation does not neces-
sarily take an individual out of a healthy response pattern. Fig-
ure 1 shows the population distribution of immune response 
strength (if something like this can be defined…) and how an 
individual within this population is shifted by an immune re-
sponse modifier (toxicant) toward immunosuppression or im-
munoactivation; only if this immunotoxic effect pushes the in-
dividual to the extremes of this distribution (out of normal, i.e., 
disease or significantly increased likelihood of disease), will 
we really see a manifestation of immunotoxicity. this means 
that we have a broad distribution of strength or type of im-
mune responses that must be considered normal. Changes, in-
duced, for example, by chemicals acting as immune response 
modifiers (toxicants), can affect either the strength of a com-
multiple sclerosis (van der Star et al., 2012; Goebels, 2007), 
there is essentially no in vitro or in silico model to screen for 
autoimmune effects of xenobiotics yet. Given the complexity 
and diversity of the different autoimmune diseases, including 
multiple genetic, environmental, and stochastic processes, it 
is rather unlikely that such alternative methods will become 
available in the near future. Mapping the respective pathways 
of toxicity in the established cases might be a first step to de-
velop a toolbox for testing such effects.
Consideration 2: 
Do environmental chemicals cause relevant 
immunotoxicity?
In 1994, Ernest Tucker stated: “Currently, the lack of clear 
evidence that humans suffer significant immunosuppression 
or defective immune responsiveness from xenobiotics calls for 
well-designed cohort studies to effectively evaluate their ef-
fects on immune functions in humans.” (Dean et al., 1994). 16 
years later, Luster and Gerberick (2010) similarily stated: “it 
is relatively difficult to determine the contribution of chronic 
low-level immunosuppression or the cumulative effect of mod-
est changes in immune function to the background incidence of 
disease in the human population”. The human epidemiological 
database is very limited owing to the lack of validated assays 
of sufficient sensitivity, the difficulty of accurately determining 
infectious disease incidence, and the high costs involved. the 
impressive reduction in infectious diseases over the last century 
due to hygiene, nutritional status, vaccines, antibiotics, etc. does 
not really allow us to discern the contribution of chemical-in-
duced immunosuppression leading to infectious complications. 
In April 2010, the US President’s Cancer Panel published the 
report “Reducing Environmental Cancer Risk” (Reuben, 2010) 
which stated that “overall cancer incidence and mortality have 
continued to decline in recent years”. Thus there is at least no 
evidence of an increasing frequency of diseases which could 
be attributed to immunotoxicity. this obviously says nothing 
about specific exposed or sensitive groups or specific types of 
infectious disease or cancer. this situation must be considered 
in the context that life expectancy has tripled (Kirkwood, 2008) 
during the period in which these chemicals were introduced. 
the pattern of environmental chemical exposure, however, is 
continuously changing. We apparently now have the cleanest 
water and air since decades but manufactured food and con-
sumer products expose us to new substances on an almost daily 
basis, prohibiting us from drawing definite conclusions on the 
chemicals’ effects on our health. 
In case of the immune system the problem is even more dif-
ficult than for other hazards: first, we are not talking about one 
organ but bone marrow, thymus, spleen, about 1000 lymph 
nodes and a similar number of Peyers’ patches in the gut, the 
lymphoid tissue associated with skin, mucosa, bronchi, gut and 
the genitourinary tract as well as the peripheral leukocytes. the 
second unique aspect is the capacity for self-restoration and 
emergency recruitment of leukocytes. If we see the immune 
system as the armies of self-defense, we understand that any 
Fig. 1: Schematic representation of the population’s 
variability in immune response and an individual within the 
population changing strength of immune response because 
of exposure to an immunotoxicant
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ponent or the pattern of responses and will normally not lead 
to disease manifestation. But, increasingly, at both extremes of 
the distribution, exposure and circumstantial factors, such as 
nutrition, comorbidities and others, will add up to compound 
the likelihood of disease manifestation. the hypothesis is put 
forward that this system very strongly buffers broad variations 
of immune responses, but that extreme dysregulation greatly 
changes the odds of disease manifestation owing to the per-
manent pressure of infectious agents at the barriers and the 
enormous resources of the immune system that, once activated 
can turn against the host.
there seems to be tremendous buffer and networked self-con-
trol against overshooting and attenuated immune response. On-
ly extreme alterations appear to result in clinical symptoms as 
the majority of immune cells are never challenged by supposed 
threats, i.e., pathogens as well as correctly or not identified ma-
lignant constituents of the body. We lack thresholds of adver-
sity for immunomodulation that do not represent an increased 
incidence of disease when the immune response is inadequate. 
this would be a prerequisite for establishing any screening for 
immunotoxic instead of immunomodulatory properties.
We know from the clinics that it usually takes drastic treat-
ments to compromise the human immune system to result in 
therapeutic immunosuppression. Some examples of doses of 
immunosuppressants that achieve immunosuppression as the 
main or a side effect:
– cyclophosphamide: 1-3 mg/kg/day (high bioavailability)
– azathioprine: 1.5-3 mg/kg/day (high bioavailability)
– methotrexate: 5-15 mg/kg/7 days (variable, moderate bio-
availability)
– glucocorticoids: 0.1-1 mg/kg/day (high bioavailability)
– cyclosporin: 2.5-15 mg/kg/day (variable, moderate bioavail-
ability)
– tacrolimus: 0.1-0.3 mg/kg/day (variable, moderate bioavail-
ability)
We might argue that these agents are optimized with regard to 
bioavailability and efficacy. Thus, we might conclude that gen-
eral industrial chemicals not targeting the immune system are 
unlikely to be more effective than intentional immunosuppres-
sants. We might derive from this a threshold of toxicological 
concern in the mg/kg/day range, which means that substances at 
less than this concentration are unlikely to result in immunosup-
pression in humans.
Immunosuppressive compounds can interact directly with 
immunocompetent cells, resulting in alteration of the status 
and/or functionality of the immune system. Characterization of 
how immunotoxicants interfere with cell signaling may lead to 
a better understanding of their molecular mechanism of action. 
Different mechanisms can lead to immunotoxicity: 
1. Chemicals can kill immune cells, resulting in bone marrow 
toxicity and immunosuppression. Compounds that can dam-
age or destroy the bone marrow will often have a profound 
immunotoxic effect, since the effectors of the immune system 
will no longer be available. Antitumor drugs, benzene, and 
ionizing radiation are examples of myelotoxic compounds. 
2. Chemicals can interfere with general or immune specific 
signaling pathways, resulting in changes in the expression 
of surface markers, cytokine production, cell differentiation 
and activation. Immunotoxic compounds can act via a recep-
tor mediated or non-receptor mediated effect. examples of 
chemicals acting through a receptor-mediated effect include 
glucocorticoids, polycyclic aromatic hydrocarbons, and can-
nabinoids, while immunotoxic compounds acting through a 
non-classical receptor mediated event include calcineurin in-
hibitors, metals, and some pesticides. 
Many substances exert immunosuppressive effects by inhibit-
ing bone marrow stem cell proliferation (cyclophosphamide, 
methotrexate), or spleen/thymus (organotin, tCDD), or by di-
rectly affecting mature leukocytes (glucocorticoids, tCDD, cy-
clophosphamide, methotrexate), e.g., by inhibiting lymphocyte 
proliferation or triggering their apoptosis. Cyclophosphamide 
was shown to selectively deplete a regulatory t cell population 
(Weir et al., 2011). Noteworthy, humans appear to be much less 
sensitive to the immunosuppressive effects of tCDD and, ap-
parently, some others than rodents or even monkeys. Because of 
the non-specific nature of some of these immunosuppressants, 
several modes of action are observed, e.g., for steroids suppres-
sion pro-inflammatory cytokine and chemokine production, up-
regulation of TGF-β, shift to anti-inflammatory TH2-responses, 
suppression of NK cell functions, and impaired dendritic cell 
activation and differentiation. Noteworthy, cytotoxic drugs also 
have various immunostimulatory effects (Zitvogel et al., 2008), 
such as increases in effector t cell stimulation and tumor im-
munogenicity as well as decreases in tumor induced immune 
suppression (Weir et al., 2011).
Immunosuppression of the granulocytes of the innate immune 
system appears to be rare, likely due to the rapid renewal of 
granulocytes from bone marrow, which can be dramatically ac-
celerated by the induction of colony-stimulating factors (Har-
tung, 1999; Hareng and Hartung, 2002). the rare (2-9 patients 
per million inhabitants per year) but potentially life-threatening 
disease agranulocytosis, if not caused intentionally by chemo-
therapy, is attributable to 70-97% to drugs (Garbe, 2007). Its 
pathogenesis is still incompletely understood, but immune me-
diation and damage to granulocytes or their hematopoietic pre-
cursors by reactive drug metabolites appear to play a role. there 
is no evidence for environmental chemicals playing a major 
role, though case reports can be found (Knutsen, 1978). they 
did not warrant test development in vivo or in vitro, but a QSAR 
has been developed to predict such effects (Díaz et al., 2003). 
therefore, macrophage effects might be more critical as they 
control granulocyte recruitment and activation. the most ad-
vanced test here is the whole blood monocyte cytokine release 
assay (see below), though variants using isolated peripheral 
blood mononuclear cells (PBMC) are also available for similar 
evaluation.
So far, we are not systematically collecting information on 
immunomodulatory effects of chemicals and drugs. A database 
of immune effects of xenobiotics might be a first step to estimate 
the role of chemicals in immune associated health burden. there 
is a National toxicology Program (NtP) database which con-
tains information on the NtP studies that have been conducted 
and one can request access to this. NtP and ePA currently are 
working on a new database that will be publicly available. 
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studies for risk assessment has proven challenging, especially 
when the immunological effects are minimal-to-moderate in 
nature (Germolec, 2004). Attempts were made to complement 
or replace them with in vitro methodologies. the workshop 
“Immunotoxicology and in vitro possibilities” (Sundwall et 
al., 1994) analyzed the then current status of in vitro methods 
for assessing immunotoxicity. At that time, experts agreed that 
there was no immediate way to replace the whole animal for 
immunotoxicology studies. On the other hand, much progress 
has been achieved regarding the reduction in the number of 
animals used, since in vitro models can be used for prescreen-
ing. At present, a tiered approach has been proposed, since use-
ful information can be obtained from regular 28-day general 
toxicity tests if increased attention is paid to the study of the 
histopathology of a large variety of lymphoid tissues, coupled 
with immunohistochemical measurements and the determina-
tion of antibody classes. Furthermore, it was established that 
the in vitro test should be validated against information gained 
from humans rather than the results from laboratory animal spe-
cies. We followed this workshop with a more extensive one in 
2003 (Gennari et al., 2005). the recommendations made then 
still stand and those not addressing sensitization are reproduced 
in table 2.
In vitro testing for immunosuppression
Before starting with in vitro tests, bioavailability should be con-
sidered. If the compound does not have appreciable bioavail-
ability, immunotoxicity is unlikely to occur. 
As a general strategy, an initial evaluation of myelotoxicity 
should be performed (tier 1). If a compound is myelotoxic, 
there may be no need to proceed with additional evaluation. the 
methodology for bone marrow culture systems is published and 
well characterized. In vitro bone marrow culture systems are 
commercially available, and they would probably only have to 
be modified slightly to accommodate in vitro exposure to test 
material. Assays of immunosuppression have been validated to 
predict the maximum tolerated dose (MtD) in humans. their 
Consideration 3: 
Determining immunosuppression in vivo  
and in vitro
In vivo testing for immunotoxicity
there are relatively few guidelines for testing compounds for 
immunotoxicity. the earliest guidelines were developed for 
pesticides in 1996 by US ePA (OPPtS 880.3550 followed by 
880.3800 and 870.7800). They reflect the NTP’s tier-testing ap-
proach (luster and Gerberick, 2010; Basketter et al., 2012) and 
typically request in vivo tests in rodents (Descotes, 2006).
For drugs, International Conference on Harmonization (ICH) 
Safety Number 8 guidance recommends a “weight-of-evidence 
approach”, i.e., alerts of immunotoxicological potential in 
standard tests should trigger specific tests. Table 1 lists changes 
that should trigger tier II testing on a case-by-case basis. Note-
worthy, activation of the immune system (hypersensitivity and 
autoimmunity) is not covered by S8. Guidance is also available 
from FDA3.
For environmental chemicals, no dedicated OeCD test guide-
lines exist, but extensions were made to 28-day repeat dose 
toxicity testing (tG 407) (Institóris et al., 1998). the european 
ReACH program does not require immunotoxicity as a standard 
information requirement. However, under short-term (28-day 
studies) and sub-chronic (90-day studies) repeated dose testing 
it requests: “Further studies shall be proposed by the registrant 
or may be required by the Agency in accordance with Article 40 
or 41 in case of: ...indications of an effect for which the avail-
able evidence is inadequate for toxicological and/or risk char-
acterisation. In such cases it may also be more appropriate to 
perform specific toxicological studies that are designed to in-
vestigate these effects (e.g. immunotoxicity, neurotoxicity)…”4. 
the most recent guidance document comes from WHO 2012 as 
Harmonization Project Document No. 10 Guidance for Immu-
notoxicity Risk Assessment for Chemicals5.
Animal tests constitute the current gold standard for immu-
notoxicology. Interpreting data from animal immunotoxicology 
3 http://www.fda.gov/downloads/Food/GuidanceRegulation/UCM078748.pdf
4 http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2006R1907:20121009:EN:PDF
5 http://www.inchem.org/documents/harmproj/harmproj/harmproj10.pdf
Tab. 1: Immunotoxic alerts in standard toxicology studies  
(i.e., 28-day repeated dose toxicity testing study in rodents)
●  Changes in total and differential white blood cell counts, i.e., leukocytopenia/leukocytosis, granulocytopenia/granulocytosis,  
or lymphopenia/ lymphocytosis;
●  Changes in clinical chemistry, i.e., serum immunoglobulin levels and albumin/globulin ratios;
●  Alterations in organ weights, i.e., thymus and spleen, and/or histology of primary and secondary lymphoid organs, i.e., bone 
marrow, thymus, spleen, draining and distant lymph nodes;
●  Increased incidence of infections;
●  Increased occurrence of tumors, in the absence of genotoxicity, hormonal effects, or liver enzyme induction;
●  Chemical retention in organs/cells of the immune system.
Hartung and Corsini
Altex 30, 4/13 417
immunization culture system based on the Mishell-Dutton assay 
(Mishell and Dutton, 1967). Recently, Koeper and Vohr (2009) 
reported that using a modification of the Mishell-Dutton assay 
with female NMRI mouse splenocytes, all six immunosuppres-
sive compounds tested (with the exception of cyclophospha-
mide) and all four non-immunotoxic compounds were correctly 
identified. Further use and development of this model is, there-
fore, recommended.
Potential effects of chemicals on cytokine expression should 
be determined. the role of cytokine transcription or production 
should be evaluated as well as the modulation of cytokine re-
ceptors. It should also be investigated if cytokine transcription 
or production is skewed (tH1/tH2 shift). It will require careful 
consideration which cytokines should be measured to obtain the 
most useful information (e.g., proinflammatory, specific immu-
noregulatory cytokines). It is recommended that a broader panel 
of cytokines than is currently used be investigated. Both basal 
and activated cytokine production should be measured, and for 
activated cytokine production, anti-CD3 and anti-CD28, lPS, 
or allergens should be used. the whole blood assay is the most 
promising option owing to its advanced stage of prevalidation.
Many assay systems are available for measuring cytokine ex-
pression (e.g., ELISA, flow cytometry, molecular biology tech-
niques, such as Rt-PCR). they are moderately expensive, and 
their feasibility is high due to wealth of published methodology 
and commercial standardization.
Potential effects on NK cells should be determined. Cytolytic 
function should be measured (this is important for innate immu-
nity). there are a variety of systems available for measuring cy-
tolytic function (e.g., whole blood, radiolabel release, flow cy-
tometry); these systems are robust and well characterized. the 
immunoregulatory function of NK cells should be evaluated 
due to the key regulatory nature of these cells. At present, such 
a system is not well described, and would require method devel-
opment. A feasible system would probably be a modification of 
suitability for use in chemical-induced immunotoxicity should 
be determined and would require prevalidation. these assays are 
relatively expensive if human cells are used, but the standardized 
nature of commercial systems should provide good feasibility.
Compounds that are not overtly myelotoxic may still selec-
tively damage or destroy lymphocytes, which are the primary 
effectors and regulators of acquired immunity. Compounds are 
therefore tested for lymphotoxicity (tier 2). this toxicity may 
result from the destruction of rapidly dividing cells by necrosis 
or apoptosis; alternatively, chemicals may interfere with cell ac-
tivation, affecting signal transduction pathways. An in vitro test 
to determine lymphotoxicity should be carried out (cell death 
by necrosis or apoptosis). Such assays would require prevali-
dation to evaluate their reliability/reproducibility. After myelo-
toxicity and overt cytotoxicity are excluded as endpoints, basic 
immune cell functionality should be assessed by performing 
specific functional assays, i.e., proliferative responses, cytokine 
production, NK cell activity, etc. (tier 3), using non-cytotoxic 
concentrations of the tested chemicals (viability >80%). For t 
cells, the stimulatory agent could be a combination of anti-CD3 
and anti-CD28 or mitogens such as concanavalin A (ConA) and 
phytohemagglutinin (PHA); for B-cells an optimum system 
would have to be developed but would be expected to be similar 
to the murine system incorporating an anti-immunoglobulin and 
cytokine or KlH. this determination may require broadening 
to include other types of immunocytes (e.g., phagocytes). these 
assays are relatively inexpensive (source material is readily 
available); the feasibility is high owing to the wealth of pub-
lished methodology.
In animals, production of t-dependent antibodies is consid-
ered to be the “gold standard”. However, there are currently no 
good systems for in vitro antibody production using human cells, 
and there is also doubt whether a primary immune response can 
actually be induced in human peripheral blood leukocytes. One 
potential starting point could be the development of an in vitro 
Tab. 2: General recommendations from the ECVAM workshop  
●  Hypersensitivity and immunosuppression are considered the primary focus for developing in vitro methods in immunotoxicology. 
Nevertheless, in vitro assays to detect immunostimulation and autoimmunity are also needed. Although developmental 
immunotoxicity is an emerging concern, there are no in vitro test models available at this time.
●  It is recommended to use a flow chart/decision tree approach to evaluate whether or not a compound is immunotoxic (initial 
screening). Detection of compounds as potential immunotoxicants can then be followed up by more detailed in vitro mechanistic 
assays (e.g., antigen-specific or redirected CTL).
●  To maximize human relevance, and due to the lack of species limitations for these assays, it is recommended that human cells be 
used for all in vitro test systems. With the exception of bone marrow assays, the source of cells should be PBL (peripheral blood 
leukocytes) from donors prescreened for health, immune reactivity, etc.
●  Although the use of primary human cells will be of the highest clinical relevance, consideration may eventually be given to the use 
of sufficiently well-characterized and validated cell lines (human or animal) for certain aspects of the test systems. It is anticipated 
that most of these assays will be amenable to a microculture format, increasing efficiency and decreasing cost.
●  The validation of an in vitro method to detect immunotoxicity must depend on high quality in vivo data. It is essential that a 
sufficiently large number of positive and negative reference compounds, including both drugs and chemicals, be tested. To this 
aim the establishment of a human database is strongly recommended. This could be accomplished by a coordinated effort from 
governmental agencies, medical institutions, and industry. Access to any extensive animal databases, when available, will also be 
helpful.
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of this type of effect being induced by low molecular weight 
chemicals. the existing whole blood assay should be consid-
ered to address this question.
Adjuvants may be included in vaccine formulations to enhance 
the immune response to a particular antigen(s). It is known that 
certain compounds can have adjuvant activity through direct or 
indirect activation of dendritic cells (DC). Indirect activation 
can also result from non-immune cells present at the site of ex-
posure to the compound.
For direct activation, human DC models are suitable, as pre-
viously described. For indirect activation the use of other cell 
models should be encouraged, depending on the route of ex-
posure, e.g., human lung epithelial cells, human keratinocytes, 
gastrointestinal tract. In the case of non-immune cells we rec-
ommend evaluation of cytotoxicity and proinflammatory me-
diator release, e.g., cytokines, chemokines.
the major limitations of in vitro immunotoxicology and fu-
ture research needs initially identified (Gennari et al., 2005) still 
stand as, ten year later, progress has been rather limited. limita-
tions and needs are listed in table 3.
the test systems under consideration for assessing chemical-
induced immunosuppression have not really changed (tab. 4). 
the existing whole blood model or other cytokine methods. the 
systems currently in use are highly reliable and reproducible; 
implementation for in vitro exposure would require additional 
development. the cost of performing these assays depends on 
the assay endpoint, but is overall relatively inexpensive; feasi-
bility is high due to extensive past use of this methodology. In 
addition, these systems will require prevalidation for exclusive 
in vitro exposure.
An assessment of the functionality of immune cells could 
also include the measurement of other mediators, e.g., hista-
mine, cytokines, eicosanoids, or activation of the complement 
cascade leading to hypersensitivity reactions. the use of the 
whole blood assay can also address the release of mediators by 
basophils (histamine) and monocytes (cytokines). Finally, the 
use of mast cell models also needs to be considered. At the mo-
ment, there is no strong evidence for a role of eosinophils being 
directly activated by compounds. Models are available.
Immunoregulation (e.g., adjuvants, superantigen)
It has been shown that lymphocytes can be directly activated 
by microbial products (superantigen concept), leading to release 
of cytokines and clinical effects. to date, there is no example 
Tab. 3: Major limitations and future research needs in in vitro immunotoxicology
●  In vitro exposure is most straightforward for direct immunotoxicants. However, materials that require biotransformation would 
require special culture systems (e.g., culture in the presence of S9 fraction).
●  Physiochemical characteristics of the test material may interfere with the in vitro system. Such characteristics may include the 
need for serum, effects of vehicle on cells (such as DMSO), and chemical binding to cells. In order to retain the viability of the cells 
at an acceptable level, in vitro exposures are often performed in 0.1% ethanol or 0.1% DMSO as maximum solvent concentration, 
thereby maximizing the exposure concentration of the xenobiotic. This is an additional limitation of in vitro systems.
●  In vitro systems do not take into account the interactions of the different components. It is difficult to reproduce the integrity of  
the immune system in vitro.
●  In vitro systems do not account for potential neuro-immuno-endocrine interactions. There is no anticipated resolution for this 
deficiency at present.
 ● The current state of technology does not allow evaluation of the induction of a memory response in vitro. Resolution of this 
deficiency will require the development of novel culture systems.
● The current state of technology does not allow evaluation of recovery (acute vs. long-term immunosuppression). Resolution of this 
deficiency will require the development of novel culture systems.
●  The current state of technology does not allow for evaluation of toxic effects on lymphoid architecture that could lead to defects in 
cellular interactions necessary for induction of immune responses (e.g., lymph nodes). Future developments in tissue engineering 
may solve this problem, but this is a long-range possibility.
●  Exclusive use of human cells may limit the ability to bridge to the preexisting database of animal immunotoxicology studies.
●  The use of ’omics should be considered for the search of new parameters and for the possibility of gene profiling after hapten 
treatment.
●  Determination of potential effects on antibody induction/production.
●  In animals, production of a T-dependent antibody (such as SRBC (sheep red blood cells)) is considered to be the gold standard. 
However, there are currently no good systems for in vitro antibody production using human cells.
●  Development of human in vitro systems will require optimization of stimulator (preferably using antigen relevant to human 
exposure, such as TT (tetanus toxin)), culture conditions, and assay endpoint(s). For these reasons, further research in this area is 
strongly recommended.
●  There is a need for research to develop in vitro models to detect autoimmunity and immunostimulation.
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strate their relevance. More recently, the same group explored 
the possibility of identifying a gene signature of direct immu-
notoxicants by testing the effects of 31 test compounds on the 
transcriptome of the human Jurkat t cell line (Shao et al., 2013). 
They confirmed that diverse modes of action are involved in di-
rect immunotoxicity and that a set of pathways or genes, rather 
than one single gene can be used to screen compounds for direct 
immunotoxicity.
One of the authors has mainly contributed to this field by the 
adaptation of the whole blood cytokine test, validated earlier 
as a pyrogen test (Hartung et al., 2001; Hoffmann et al., 2005; 
Daneshian et al., 2009; Schindler et al., 2009), while the other 
has used the whole blood assay as an in vitro assay to character-
ize the molecular mechanisms of action of some pesticides and 
as mean to assess the effects of pesticides in human exposed 
workers ex vivo (Corsini et al., 2005, 2007). 
As a prototypic example the whole blood cytokine test shall be 
discussed in more detail here. Both monocyte and lymphocyte 
functions (Hermann et al., 2003) can be assessed using selec-
tive stimuli (langezaal et al., 2001). this observation advanced 
to a prevalidation study (langezaal et al., 2002). the in vitro 
results were expressed as IC50 values for immunosuppression, 
and SC4 (4-fold increase) values for immunostimulation. the 
whole blood cytokine results reflected immunomodulation from 
Cytokine production and lymphocyte proliferation have been 
pre-validated (Carfì et al., 2007). the human t cell activation 
assay was selected as the most promising of the investigated in 
vitro immunotoxicity tests. this assay is based on CD3/CD28-
mediated t cell activation using proliferation and cytokine re-
lease (TNFα and IFNγ) as read-out parameters. To pre-validate 
the human t cell activation assay, 20 compounds were select-
ed, of which 10 were immunosuppressive and 10 non-immu-
nosuppressive. Statistical analyses revealed that the human t 
cell activation test had a “sensitivity” (correct prediction of im-
munosuppressive chemicals) of 76% and a “specificity” (cor-
rect prediction of non-immunosuppressive chemicals) of 83% 
(manuscript in preparation). the human t cell activation assay 
may be a promising candidate for in vitro evaluation of immu-
nosuppressive activity.
Immunotoxicogenomics represents a novel approach to in-
vestigate immunotoxicity. Hochstenbach et al. (2010) have 
recently reported a set of 48 genes that can be used to distin-
guish immunotoxic from non-immunotoxic compounds using 
human peripheral blood mononuclear cells. these genes might 
be considered candidate biomarker genes for immunotoxicity 
screening. However, even if many of the annotated genes appear 
to be immunologically relevant, in vivo studies in the human 
population or in experimental models are necessary to demon-
Tab. 4: Test systems under consideration for assessing chemical-induced immunosuppression    
Model
Myelotoxicity CFU-GM assay 
Lymphotoxicity and 
proliferation 
 
 
        
 
Antibody production, e.g., 
Mishell-Dutton assay
 
Cytotoxic lymphocyte function 
(CTL)
 
 
NK cell function, e.g., K562 
killing 
 
 
 
 
Whole blood cytokine release
 
 
Dendritic cell function
Comment
Validated for determining the starting dose of chemotherapies 
in human trials
Human peripheral blood lymphocytes (whole blood or 
PBMC) or rodent splenocytes are typically used. Polyclonal 
stimuli include anti-CD3, anti-CD28, plant lectins such as 
concanavalin A (ConA) and phytohemagglutinin (PHA), 
superantigens, etc. Mixed lymphocyte reactions possible but 
less used for immunotoxicity.
Gold standard in animals ex vivo but highly variable in vitro, 
originally mouse splenocytes, later human cells
 
Allogeneic cells stimulate rodent splenocytes (e.g., P815 
murine mastocytoma cell line) or human blood lymphocytes 
(e.g., Jurkat leukemic cell line) for killing by CTL. Rarely used 
for in vitro immunotoxicity.
Sensitive to toxicants; use also ex vivo. A number of 
chemicals have been shown to impair NK cell activity. 
However, direct evidence for clinically significant pathologic 
consequences, such as infections or immunosuppression-
related cancer in human beings exposed to these chemicals, 
is lacking.
Pre-validated assay for both monocyte and lymphocyte 
cytokine release, simple to perform on primary human cells  
in vitro and ex vivo.
Very well characterized for the in vitro assessment of 
contact allergens. Less well established endpoint for 
immunosuppression.
Reference(s)
Pessina et al., 2001;  
Negro et al., 2001 
Carfì et al., 2007 
 
 
 
 
 
Mishell, 1967;  
Dutton and Mishell, 1967;  
Wood et al., 1992 
House and Thomas, 1995 
 
 
 
Morales and Ottenhof, 1983; 
Roder et al., 1980;  
Descotes and Ravel, 2005;  
Kim et al., 2007;  
Blom et al., 2009 
 
Langezaal et al., 2001, 2002 
 
 
Coutant et al., 1999; Hymery et 
al., 2006 
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consider other axes of the immune system from complement 
and other humoral factors, such as antibodies and surfactants, 
to eosinophils, neutrophilic granulocytes, B-cells or tissue im-
mune cells, etc. the hope must be that a limited number of pop-
ulations and immune functions are sufficiently representative to 
allow us to create a battery of tests that covers the effects of 
xenobiotics on the immune system. Notably, also an immune 
challenge in vivo will only probe some of these defense lines, 
and therefore the reliance on whole animal studies does not nec-
essarily overcome this problem.
Consideration 4: 
Is there developmental immunotoxicity?
A particular aspect of the immune system is that it develops 
rather late in life. For example, thymus development lasts at 
least until puberty. Over the last couple of years, the need to 
consider the special vulnerability of the developing immune 
system has been discussed (Burns-Naas et al., 2008; DeWitt et 
al., 2012; Collinge et al., 2012; Dietert, 2008). Developmental 
immunotoxicology might predispose children to diseases such 
as childhood asthma, allergic diseases, autoimmune conditions, 
and childhood infections, which have been on the rise in re-
cent decades. Our knowledge, especially across species, is still 
small. there may be critical windows of vulnerability of the 
developing immune system, such as:
– Hematopoietic stem cell formation
– Migration of hematopoietic stem cells to fetal liver and thy-
mus, early hematogenesis and migration of macrophages to 
tissues
– establishment of the bone marrow as a primary site of hemat-
opoiesis and bone marrow and thymus as primary lymphopoi-
esis sites for B and t cells, respectively
– Functional development and maturation of immunocompe-
tence
However, there are no corresponding non-genetic immune 
syndromes in the clinic. Granted, infections in the very young 
are often more severe compared to adults, and delays or im-
pairments of these processes could further increase vulnerabil-
ity. An approach in which pregnant animals are continuously 
exposed to test chemicals is currently favored to address all 
critical windows of developmental immunotoxicity at once. 
However, in general, research into this has been very limited. 
It will only be of major importance if there are substances that 
are developmental immunotoxicants but do not affect adults. A 
framework for developmental immunotoxicity has been pro-
posed that favors the rat (Holsapple et al., 2005) though immu-
nological tools are more limited here, although they do allow 
inclusion into standard guideline assays. In vitro approaches 
are rare to non-existent.
the development of in vitro and ex vivo tools for develop-
mental immunotoxicology will be of critical importance when 
transitioning from the two-generation to an extended one-gen-
eration study for reproductive toxicology, where one of the key 
extensions requested is developmental immunotoxicity. If this 
in vivo studies. A sensitivity of 67% and a specificity of 100% 
for the combined endpoints in the test were calculated. Results 
were reproducible, and the method could be transferred to an-
other laboratory, suggesting the potential use of the test in im-
munotoxicity testing strategies. Advantages of the human blood 
cell based in vitro test include (Gennari et al., 2004):
– Species differences between humans and animals are avoid-
ed.
– Human primary cells are employed in their physiological pro-
portions and environment, avoiding preparation and cultiva-
tion artifacts.
– Culture techniques are extremely simple, e.g., allowing incu-
bation in thermoblocks.
– Cryopreserved blood overcomes problems of availability, 
standardization, and risk of infection.
– In vitro testing is less expensive and time-consuming than in 
vivo testing.
– the same test can be employed ex vivo and in vitro.
– the number of compounds and concentrations tested can be 
increased.
– the amount of substance required is dramatically reduced, 
allowing testing at earlier stages of drug development.
– effects on different blood cell populations can be tested in a 
single model.
– Changes of cellular immune response can be quantified, ena-
bling potency testing.
Noteworthy, cryopreserved whole blood has been developed and 
validated for the pyrogen test (Schindler et al., 2004, 2006) and 
is commercially available. However, this has not been adapted 
for immunotoxicity testing to a major extent, though the advan-
tages of availability, standardization, and pretesting for both ab-
normal responses and infectious threats are evident.
A very interesting opportunity, as mentioned above, is the fact 
that the very same test can be performed ex vivo after immu-
nomodulatory treatment or intoxication (Hartung et al., 1995a; 
von Aulock et al., 2004; elsässer-Beile et al., 1993). the exam-
ple of the whole blood immunotoxicity assay shows that with 
the relatively easy access to human primary cells, the field is 
predestined to use cells from the target species of interest. Note-
worthy, protocols for other immune function assays using whole 
blood incubations are available affording similar advantages 
(Fletcher et al., 1987; Bloemena et al., 1989).
It should be noted that the array of in vivo, ex vivo, and in 
vitro immunotoxicity assays is still incomplete. With the growth 
of our understanding of immunological phenomena, new needs 
emerge, e.g., the call for assessing effects on regulatory t cells 
(Corsini et al., 2011): “The concept of regulatory or suppres-
sor cells having a role in chemical-induced immune system 
toxicology has been somewhat understudied. However, it is 
now recognized that Tregs play a critical role in maintaining 
the careful balancing act that allows the immune system to re-
spond appropriately in the face of infection or disease, resolve 
when the challenge has diminished, and fail to respond to self-
antigens. As shown by the speakers in this symposium, various 
immunoregulatory T cell subsets may be induced by environ-
mental chemicals and protein allergens.” Similarly, we might 
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10 times more bacteria than its own cells. the gut contains 
1-2 kg of bacteria containing about 50 g of endotoxin (ernst 
Rietschel, Borstel, personal communication). Many, especially 
topical, toxicities include breakdown of skin and mucosal bar-
riers, allowing translocation of bacteria and lPS inter alia. 
the contribution of this to the manifestation of irritation by 
chemicals has to the best of the authors’ knowledge not been 
addressed.
We might turn an argument around to substantiate the hy-
pothesis that, especially in acute oral intoxications, the ani-
mals do not die from the toxin but from secondary effects to 
the gastrointestinal tract (GIt) as argued already in this series 
(Hartung, 2008): it has been documented in at least three major 
attempts that cytotoxicity correlates pretty well with acute oral 
toxicity (see Halle register, MeIC study and the more recent 
ICCVAM/NICeAtM/eCVAM validation study). Actually, this 
makes little sense if we assume that the substances are taken 
up, distributed and metabolized with complex kinetics, and can 
affect more than 400 different tissues with various sensitivities. 
Might it be that the animal experiment simply measures cyto-
toxicity to the GIt epithelium, which results in translocation 
of bacteria? Ironically, this would mean that we can pretty well 
predict this animal test in vitro, but the animal test measures a 
phenomenon (cytotoxicity to the intestine) that is irrelevant for 
humans (we would vomit – which rodents cannot do – or at-
tempt to remove the intoxication before it reaches the intestine, 
supply intensive care treatment, etc.). Instead of our 9 million 
€ effort of A-Cute-tox (http://www.acutetox.org/), a well-de-
signed series of animal experiments might demonstrate that the 
reference method is meaningless. 
there is also strong evidence for involvement of immune 
cells likely activated by translocation of bacteria (Su, 2002; 
Nolan, 2010) in the effects of classic hepatotoxins (laskin 
and Pendino, 1995; leist et al., 1998; luster et al., 2001): data 
exist for paracetamol, cocaine, nitrosamine, galactosamine, 
lead withdrawal, thioacetamide, α-amanitin, actinomycin D, 
diethyl-dithiocabarmate, phalloidin, CCl4, cyproterone ac-
etate, 1,2-dichlorobenzene, cadmium, allyl alcohol, heliotrine, 
ischemia-reperfusion, microcystine, and others. Often tNF, a 
key early response cytokine to lPS and bacteria released by 
Kupffer cells, the macrophages of the liver, is key here: for ex-
ample, the toxicity of CCl4, the prototype of a directly acting 
hepatotoxin, is inhibited by scavenging tNF with recombinant 
soluble tNF-receptor constructs (Czaja et al., 1994). leist et al. 
(1997) proved the role of tNF and hepatocyte apoptosis during 
the poisoning of mice with α-amanitin or with actinomycin D, 
respectively, as these toxicities were also inhibited by passive 
immunization of mice against TNF. Inflammation-induced in-
creases in susceptibility to toxicity are not limited to liver but, 
e.g., also sensitize to the toxic effects on the respiratory tract, 
kidney, and lymphoid tissue (Ganey and Roth, 2001).
Immunomodulation also plays a key role in carcinogenicity. 
Immunosuppressive activity is important as neoplastic cells 
frequently have antigenic properties that permit their detec-
tion and elimination by normal immune system function. two 
decades ago, luster et al. (1992) investigated the relationship 
aspect cannot be satisfied without the use of additional animal 
groups savings in animals and costs will be minimal compared 
to the two-generation study. It has to be recalled that this rep-
resents one of the largest animal consuming tests and a key 
burden of the ReACH program (Hartung and Rovida, 2009; 
Rovida and Hartung, 2009; Bremer et al., 2007; Rovida et al., 
2011). 
Consideration 5: 
Is there an immune component in many other 
toxicities?
the answer is clearly yes, and it is an underdeveloped area of re-
search. Although not associated with specific immunity, a third 
common immunotoxic effect is inflammation, which contrib-
utes to tissue and organ damage (luster amd Rosenthal, 1993). 
Inflammation is triggered by necrosis, e.g., as a consequence 
of cytotoxicity. tissue destruction is normally accompanied 
by an inflammatory reaction. One hallmark of this inflamma-
tory process is the infiltration by different subsets of leukocytes 
from the circulation into the wounded site (DiPietro, 1995). 
Chemokines, a subgroup of cytokines, are responsible for this 
site-directed migration of immune cells. Interestingly, we know 
little about how this is achieved. the most potent inducers of 
chemokine release are bacterial components such as lipopoly-
saccharide (lPS) of Gram-negative bacteria. even though bac-
teria are not always present in wounded tissue, e.g., in ischemia, 
sterile trauma or other disturbances of tissue homeostasis like 
fibrosis, chemokine release, and infiltration of leukocytes into 
the damaged tissue may occur, triggered by damage associated 
molecular patterns or DAMPs, which includes ROS, uric acid, 
hyaluronic acid fragments, AtP, etc. 
Components of destroyed cells might act as inducers of in-
flammation and leukocyte migration. We carried out a rather 
simple series of experiments, where human blood leukocytes 
were brought into contact with human cells (Schneider and Har-
tung, 2001): no cytokine release was induced if the cells were 
intact. to investigate the effect of necrotic cells, we challenged 
human whole blood, with a cell-lysate of a human fibroblast 
cell line (IMR-90). Under these conditions, we found a concen-
tration- and time-dependent, selective induction of the chemo-
kines Il-8 and MCP-1 measured by elISA. A similar release of 
these chemokines was measured in isolated human PBMC and 
elutriation-purified human monocytes after stimulation with the 
IMR cell lysate. to exclude possible contamination of the lysate 
or the cell culture by mycoplasma or endotoxin, which would 
also cause a chemokine secretion, mycoplasma were excluded 
by a commercial elISA and endotoxin by limulus amoebocyte 
lysate test as well as the lack of effect of polymyxin B, a lPS-
neutralizing compound. It would be very interesting to identify 
the components of the cell-lysate responsible for the chemokine 
induction and to compare different human cell-lines or primary 
cells as to their ability to induce chemokines. 
The strongest trigger of inflammation, however, is micro-
bial stimulation. We often forget that the human body carries 
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Not only sterile inflammation appears to play a role in the 
toxic effects of chemicals. Only slowly, the interplay of toxic 
damage and infection is beginning to be addressed (Ilbäck and 
Friman, 2007; Feingold et al., 2010). Taken together, the inflam-
matory component of various toxicities is underappreciated. It 
might be one of the components we lack when reproducing the 
hazardous effects of test substances in vitro. Including tests of 
immunomodulatory and pro-inflammatory effects of substances 
in integrated testing strategies (ItS) must thus be very strongly 
encouraged.
Consideration 6: 
The future of non-animal immunotoxicity testing
Many areas of toxicity are currently embracing new concepts, 
which are based on new technologies and the integrated use of 
information. the infamous NRC report Toxicity Testing for the 
21st Century: A Vision and a Strategy, following the strategic 
plan for the US National toxicology Program, has initiated 
tremendous efforts as have legislations in europe on cosmetic 
and chemical safety as summarized elsewhere (Hartung, 2009b, 
2010a,b). Slowly, a roadmap is evolving that can show us how 
to put the various elements together (Hartung, 2009a; Basketter 
et al., 2012). Immunotoxicology is left a little aside, as it is not a 
routine testing requirement for chemical safety, which prompted 
most of these developments. Unfortunately, the new european 
biocide and plant protection product legislation does not place 
the same emphasis on new and alternative methods as, for ex-
ample, REACH (Ferrario and Rabbit, 2012). However, the field 
is starting to embrace the new concepts (luebke, 2012). Op-
portunities lie especially in the mapping of pathways of toxicity 
(Hartung and McBride, 2011), integrated testing strategies (Har-
tung et al., 2012), and organotypic cultures, as promoted under 
human-on-a-chip approaches (Hartung and Zurlo, 2012). their 
integration toward a systems toxicology is still only emerging 
(Hartung at al., 2012), but there is tremendous potential for 
immunotoxicology. A combination of various in vitro tests to 
predict in vivo immunotoxicology has never been attempted, 
though a relatively small number of endpoints appear to reflect 
animal immunotoxicity.
Immunotoxicology appears to be less a concern as a stand-
alone health effect but more as a mechanism contributing to 
many, if not all, manifestations of toxicity of chemicals. thus 
we see less potential of promoting new information require-
ments by test guidelines but rather want to encourage the in-
clusion of mechanistic tests into the ITS to reflect the adverse 
outcome pathways for most manifestations of toxicity.
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